Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response

Satyanarayana R. Pondugula, Sridhar Mani

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Pregnane xenobiotic receptor (PXR) is an orphan nuclear receptor that regulates the metabolism of endobiotics and xenobiotics. PXR is promiscuous and unique in that it is activated by a diverse group of xenochemicals, including therapeutic anticancer drugs and naturally-occurring endocrine disruptors. PXR has been predominantly studied to understand its regulatory role in xenobiotic clearance in liver and intestine via induction of drug metabolizing enzymes and drug transporters. PXR, however, is widely expressed and has functional implications in other normal and malignant tissues, including breast, prostate, ovary, endometrium and bone. The differential expression of PXR and its target genes in cancer tissues has been suggested to determine the prognosis of chemotherapeutic outcome. In addition, the emerging evidence points to the implications of PXR in regulating apoptotic and antiapoptotic as well as growth factor signaling that promote tumor proliferation and metastasis. In this review, we highlight the recent progress made in understanding the role of PXR in cancer, discuss the future directions to further understand the mechanistic role of PXR in cancer, and conclude with the need to identify novel selective PXR modulators.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalCancer Letters
Volume328
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Pregnanes
Xenobiotics
Neoplasms
Therapeutics
Pharmaceutical Preparations
Orphan Nuclear Receptors
Endocrine Disruptors
Neoplasm Genes
Endometrium
Intestines
Prostate
Ovary
Intercellular Signaling Peptides and Proteins
Breast

Keywords

  • Cancer
  • Dog
  • Drug resistance
  • Endocrine disruption
  • PXR

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. / Pondugula, Satyanarayana R.; Mani, Sridhar.

In: Cancer Letters, Vol. 328, No. 1, 01.01.2013, p. 1-9.

Research output: Contribution to journalArticle

Pondugula, Satyanarayana R. ; Mani, Sridhar. / Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. In: Cancer Letters. 2013 ; Vol. 328, No. 1. pp. 1-9.
@article{f88f8f16061c4d219319e7528247ba0f,
title = "Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response",
abstract = "Pregnane xenobiotic receptor (PXR) is an orphan nuclear receptor that regulates the metabolism of endobiotics and xenobiotics. PXR is promiscuous and unique in that it is activated by a diverse group of xenochemicals, including therapeutic anticancer drugs and naturally-occurring endocrine disruptors. PXR has been predominantly studied to understand its regulatory role in xenobiotic clearance in liver and intestine via induction of drug metabolizing enzymes and drug transporters. PXR, however, is widely expressed and has functional implications in other normal and malignant tissues, including breast, prostate, ovary, endometrium and bone. The differential expression of PXR and its target genes in cancer tissues has been suggested to determine the prognosis of chemotherapeutic outcome. In addition, the emerging evidence points to the implications of PXR in regulating apoptotic and antiapoptotic as well as growth factor signaling that promote tumor proliferation and metastasis. In this review, we highlight the recent progress made in understanding the role of PXR in cancer, discuss the future directions to further understand the mechanistic role of PXR in cancer, and conclude with the need to identify novel selective PXR modulators.",
keywords = "Cancer, Dog, Drug resistance, Endocrine disruption, PXR",
author = "Pondugula, {Satyanarayana R.} and Sridhar Mani",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2012.08.030",
language = "English (US)",
volume = "328",
pages = "1--9",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response

AU - Pondugula, Satyanarayana R.

AU - Mani, Sridhar

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Pregnane xenobiotic receptor (PXR) is an orphan nuclear receptor that regulates the metabolism of endobiotics and xenobiotics. PXR is promiscuous and unique in that it is activated by a diverse group of xenochemicals, including therapeutic anticancer drugs and naturally-occurring endocrine disruptors. PXR has been predominantly studied to understand its regulatory role in xenobiotic clearance in liver and intestine via induction of drug metabolizing enzymes and drug transporters. PXR, however, is widely expressed and has functional implications in other normal and malignant tissues, including breast, prostate, ovary, endometrium and bone. The differential expression of PXR and its target genes in cancer tissues has been suggested to determine the prognosis of chemotherapeutic outcome. In addition, the emerging evidence points to the implications of PXR in regulating apoptotic and antiapoptotic as well as growth factor signaling that promote tumor proliferation and metastasis. In this review, we highlight the recent progress made in understanding the role of PXR in cancer, discuss the future directions to further understand the mechanistic role of PXR in cancer, and conclude with the need to identify novel selective PXR modulators.

AB - Pregnane xenobiotic receptor (PXR) is an orphan nuclear receptor that regulates the metabolism of endobiotics and xenobiotics. PXR is promiscuous and unique in that it is activated by a diverse group of xenochemicals, including therapeutic anticancer drugs and naturally-occurring endocrine disruptors. PXR has been predominantly studied to understand its regulatory role in xenobiotic clearance in liver and intestine via induction of drug metabolizing enzymes and drug transporters. PXR, however, is widely expressed and has functional implications in other normal and malignant tissues, including breast, prostate, ovary, endometrium and bone. The differential expression of PXR and its target genes in cancer tissues has been suggested to determine the prognosis of chemotherapeutic outcome. In addition, the emerging evidence points to the implications of PXR in regulating apoptotic and antiapoptotic as well as growth factor signaling that promote tumor proliferation and metastasis. In this review, we highlight the recent progress made in understanding the role of PXR in cancer, discuss the future directions to further understand the mechanistic role of PXR in cancer, and conclude with the need to identify novel selective PXR modulators.

KW - Cancer

KW - Dog

KW - Drug resistance

KW - Endocrine disruption

KW - PXR

UR - http://www.scopus.com/inward/record.url?scp=84868497825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868497825&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.08.030

DO - 10.1016/j.canlet.2012.08.030

M3 - Article

C2 - 22939994

AN - SCOPUS:84868497825

VL - 328

SP - 1

EP - 9

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -